This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 01
  • /
  • Shire and Baxalta to merge in $32 billion transact...
Industry news

Shire and Baxalta to merge in $32 billion transaction

Read time: 1 mins
Last updated: 12th Jan 2016
Published: 12th Jan 2016
Source: Pharmawand
Shire plc,and Baxalta Incorporated announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta. Under the agreement, Baxalta shareholders will receive $18.00 in cash and 0.1482 Shire ADS per Baxalta share. Based on Shire�s closing ADS price on January 8, 2016, this implies a total current value of $45.57 per Baxalta share, representing an aggregate consideration of approximately $32 billion. The exchange ratio is based on Shire�s 30-day trading day volume weighted average ADS price of $199.03 as of January 8, 2016, which implies a total value of $47.50 per Baxalta share. The value of the offer, as of Shire�s January 8, 2016 closing ADS price, represents a premium of approximately 37.5% to Baxalta�s unaffected share price on August 3, 2015, the day prior to the public announcement of Shire�s initial offer for Baxalta. This will provide Baxalta shareholders with approximately 34% ownership in the combined company. The parties expect the transaction to close mid-2016.
How do you prefer to access medical updates and information?

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.